Ms Mullarky has joined Tekmira effective immediately and will have responsibility for strategic planning and business development including securing additional licensing and collaborative R&D agreements for Tekmira’s technology.
Dr Lutwyche joined Tekmira’s subsidiary company, Protiva Biotherapeutics, in February 2008, and has responsibility for manufacturing, process development and quality control for all Tekmira product candidates as well as supporting Tekmira’s collaborative partners as they advance products based on Tekmira’s technology.
Mark Murray, president and CEO of Tekmira, said: “We are extremely pleased to add Tammy and Peter to our executive management team as each bring significant experience in their respective fields. These appointments further support our corporate priorities of advancing proprietary siRNA product candidates and licensing our leading RNAi technology to the pharmaceutical industry.”